Biocom California Names Juvena CEO Hanadie Yousef as One of Ten Recipients of Its 7th Annual Catalyst Award, Recognizing the Most Inspiring and Driven Minds Sparking Meaningful Change to Human Health
The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of Aging
Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
Discussing longevity insights among financial and biotech leaders at the BioFuture Conference, Juvena CEO, Hanadie Yousef, PhD explores the role of secreted proteins in targeting chronic and age-related diseases.
Banmeet Anand, PhD
Dr. Banmeet Anand’s more than 20 years experience in the discovery and development of antibodies encompasses fusion proteins, naked, ADCs and bi-specific antibodies; small molecules, and cellular therapies (NK-T, CAR-T) at biotechs and large pharma including Harpoon (a subsidiary of Merck & Co. inc.), Astellas and Genentech.
As senior vice president of drug development Dr. Anand leads development of Juvena’s biological assets including the pre-clinical, non-clinical and IND-enabling studies.
Prior, he served as Senior Vice President of Translational Medicine at Harpoon Therapeutics (a subsidiary of Merck & Co. Inc.) where he led toxicology, pharmacology, biomarkers, non-clinical/clinical PK/PD, companion diagnostics including IND-enabling studies supporting Harpoon’s proprietary TriTAC biologics (T-cell engagers) portfolio. Dr. Anand previously held management and scientific positions at Molecular Templates, NantKwest (ImmunityBio), Astellas (Agensys) and Genentech where he was involved in early and late development of multiple approved drugs such as RITUXAN®, PADCEV® and OCREVUS®.
Dr. Anand received his PhD in Pharmaceutical Sciences and Chemistry from the University of Missouri-Kansas City.
Learn more about Dr. Banmeet Anand
Colin Hislop, MD
As SVP Clinical Development, Dr. Colin Hislop leads Juvena’s clinical-stage drug candidates. His 36-year tenure in drug development and life sciences spans multinational roles across therapeutic areas at companies including Lilly (formerly Eli Lilly & Company), Proctor & Gamble Pharmaceuticals, Peninsula Therapeutics, Versartis Inc. Anthera Pharmaceuticals and most recently Eiger BioPharnaceuticals. His expertise encompasses early and late-stage clinical development as well as the successful prosecution of multiple drug approvals.
Just prior to Juvena, Dr. Hislop helped lead the successful prosecution of an NDA (2020) and MAA (2022) for lonafarnib to treat an ultra-rare genetic disease called Hutchinson-Guilford Progeria Syndrome. Other roles include Chief Medical Officer at Versartis Inc.; SVP and Chief Medical Officer at Anthera Pharmaceuticals where he served on the leadership team to take the Company public.
Dr. Hislop obtained an undergraduate degree in Medical Biochemistry from the University of Surrey and his medical degree from the Middlesex Hospital Medical School, University of London.
Learn more about Dr. Colin Hislop
Bernard (Barney) D. King, MD, MBA, RAC (US, EU)
Dr. King brings more than 25 years’ experience managing business and development operations in the pharmaceutical, medical device, biotechnology and CRO (Contract Research Organization) industries to his role as Chief Medical Officer at Juvena Therapeutics. Leveraging his expertise in life science product development planning and execution and in due diligence consulting for venture capital, investment, and pharmaceutical firms, Dr. King oversees all aspects of Juvena’s clinical development and medical affairs.
Prior to his role at Juvena, Dr. King directed, or has been directly involved in, development programs for more than 100 pharmaceutical, medical device and biologics products across diverse f therapeutic areas and overseen more than 250 clinical trials globally – experiences he captures in his book “Get It Right The First Time! Pharmaceutical Product Development: Intelligent Solutions for Challenging Issues.”
Dr. King graduated cum laude from the University of Notre Dame, majoring in English and Preprofessional Studies, and received his MD from the Ohio State University College of Medicine. He is board certified in Cardiology and Internal Medicine. He received his MBA from the Wharton School of the University of Pennsylvania.
Learn more about Bernard
Steven James, MS
Steven James has over 35 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Mr. James was most recently president, Chief Executive Officer and director of Pionyr Immunotherapeutics until it was acquired by Ikena Oncology. Previously, he was president, Chief Executive Officer and director of Labrys Biologics until it was acquired by Teva Pharmaceuticals.
Prior to Labrys, Mr. James was president, Chief Executive Officer and director of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Mr. James is currently a director of Allakos Inc. Ventus Therapeutics and Lyterian Therapeutics. He was formerly the chairman of Antiva Biosciences, and a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).
Learn more about Steven
